阿拉丁(688179.SH):就申請向不特定對象發行可轉債 收到第二輪審核問詢函
格隆匯11月18日丨阿拉丁(688179.SH)公佈,公司於2021年11月18日收到上海證券交易所出具的《關於上海阿拉丁生化科技股份有限公司向不特定對象發行可轉債申請文件的第二輪審核問詢函》。上交所審核機構依法對公司提交的向不特定對象發行可轉債申請文件進行了審核,並形成了第二輪問詢問題。
公司將與本次發行相關中介機構按照上述《問詢函》要求,對問詢問題進行逐項落實後以臨時公吿的形式披露問詢回覆,並在規定期限內將有關材料報送至上交所受理部門。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.